Proqr Therapeutics (PRQR) Stock Price, Quote & News

Company Profile

ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic diseases. The company also develops AX-2402, which targets methyl CpG binding protein 2 mutations for Rett...

Industry: Biotechnology

Sector: Healthcare

Phone: 31 88 166 7000

Website: www.proqr.com

Address:

Zernikedreef 9, Leiden, Netherlands

Filvul Jul. 2 at 2:12 PM

$PRQR

0 · Reply

Filvul Jul. 2 at 11:03 AM

$PRQR

0 · Reply

justfacts1 Jul. 1 at 5:20 PM

$PRQR first open market buy in company history!

1 · Reply

justfacts1 Jul. 1 at 5:19 PM

$PRQR

0 · Reply

Geert07 Jul. 1 at 10:39 AM

$PRQR $PRQR Insider buying is always a good indication. Sign of confidence.

1 · Reply

struminbanjobio Jul. 1 at 4:44 AM

$PRQR run up locked in with insiders buying, $LLY loaded up and tutes bought more $SLS $ABVX

0 · Reply

ACH50 Jul. 1 at 2:20 AM

$PRQR Bart Filius in with 150,000 share purchase. This gentleman has shared good company, Galapagos, Sanofi…it’s all starting to come together, finally…

0 · Reply

FilingTracker Jun. 30 at 8:02 PM

$PRQR Insider started a new position: https://filingtracker.ai/filing/1612940/0001104659-26-079316

0 · Reply

ACH50 Jun. 30 at 12:56 PM

$PRQR let’s be realistic, Lilly’s continued financial contributions after all these years means there is something there worth devoting resources to, not to mention platform just got derisked! While advancements in the underlying tech will come much faster now with AI & Gingko. This should at the very least be trading at $3.50 with recent dilution considered. Time to rerate.

1 · Reply

struminbanjobio Jun. 29 at 11:29 PM

$SLS $PRQR big movers today 🥳🥳😉😉

0 · Reply

ProQR Therapeutics price target lowered to $10 from $14 at Raymond James

2026-06-26T08:40:08.000Z - 8 days ago

ProQR Therapeutics price target lowered to $10 from $11 at JonesResearch

2026-06-26T00:55:07.000Z - 9 days ago

ProQR Therapeutics price target lowered to $3 from $4 at Chardan

Jun 25, 2026, 7:00 AM EDT - 9 days ago

ProQR Therapeutics Slides: Conference presentation

2026-06-25T10:40:22.000Z - 9 days ago

ProQR Therapeutics prices 27.62M shares at $1.81 in registered direct offering

LLY

2026-06-25T10:35:33.000Z - 9 days ago

ProQR Therapeutics announces positive Phase 1 data for AX-0810

Jun 25, 2026, 6:35 AM EDT - 9 days ago

ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement

Jun 25, 2026, 6:25 AM EDT - 9 days ago

ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform

May 12, 2026, 7:00 AM EDT - 7 weeks ago

ProQR Announces First Quarter 2026 Operating and Financial Results

May 12, 2026, 7:00 AM EDT - 7 weeks ago

ProQR Therapeutics Earnings release: Q1 2026

May 11, 2026, 8:00 AM EDT - 7 weeks ago

ProQR Announces Multiple Upcoming Scientific Conference Presentations Highlighting the Breadth of its Axiomer™ RNA Editing Platform

May 4, 2026, 8:00 AM EDT - 2 months ago

ProQR Announces Annual General Meeting of Shareholders to be Held June 2, 2026

Apr 30, 2026, 8:00 AM EDT - 2 months ago

ProQR Announces Nomination of Dr. Lykke Hinsch Gylvin to its Board of Directors

2026-04-08T20:45:41.000Z - 3 months ago

ProQR Therapeutics management to meet with Cantor Fitzgerald

2026-04-08T20:40:37.000Z - 3 months ago

ProQR Therapeutics management to meet with Oppenheimer

Apr 8, 2026, 4:00 PM EDT - 3 months ago

ProQR Highlights Pipeline Expansion and Multiple Upcoming Clinical Catalysts at Investor and Analyst Event

Apr 8, 2026, 10:00 AM EDT - 3 months ago

ProQR Therapeutics Transcript: Status update

Apr 8, 2026, 10:00 AM EDT - 3 months ago

ProQR Therapeutics Press release: Status update

Apr 8, 2026, 10:00 AM EDT - 3 months ago

ProQR Therapeutics Slides: Status update

Apr 8, 2026, 8:00 AM EDT - 3 months ago

ProQR Announces Partnership with Ginkgo Bioworks and Formation of AI Advisory Board

Mar 25, 2026, 8:00 AM EDT - 3 months ago

ProQR to Host Virtual Investor and Analyst Event Highlighting Pipeline on April 8, 2026

2026-03-12T11:46:03.000Z - 4 months ago

ProQR Therapeutics assumed with an Outperform at Oppenheimer

2026-03-12T11:10:29.000Z - 4 months ago

ProQR Therapeutics reports FY25 EPS (EUR 0.40) vs (EUR 0.32) last year

Mar 12, 2026, 7:00 AM EDT - 4 months ago

ProQR Announces Year End 2025 Operating and Financial Results

Mar 12, 2026, 7:00 AM EDT - 4 months ago

ProQR Therapeutics Annual report: Q4 2025

Mar 12, 2026, 7:00 AM EDT - 4 months ago

ProQR Therapeutics Earnings release: Q4 2025

Mar 11, 2026, 3:25 PM EDT - 4 months ago

ProQR Therapeutics Transcript: The Citizens Life Sciences Conference 2026

Mar 3, 2026, 4:30 PM EST - 4 months ago

ProQR Announces Webcast of Presentation at the 2026 Citizens Life Sciences Conference

2026-02-19T15:50:54.000Z - 4 months ago

ProQR Therapeutics participates in a conf call hosted by Cantor Fitzgerald

2026-02-09T13:05:14.000Z - 5 months ago

ProQR Therapeutics directors Dinko Valerio, Alison Lawton to depart

Feb 9, 2026, 8:00 AM EST - 5 months ago

ProQR Announces Planned Changes to Board Composition

2026-01-08T13:15:17.000Z - 6 months ago

ProQR announces initial safety, PK data from Phase 1 trial of AX-0810

LLY

Jan 8, 2026, 8:00 AM EST - 6 months ago

ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK Data, Development Candidate Selections, and 2026 Outlook

Dec 4, 2025, 8:20 AM EST - 7 months ago

ProQR Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 1, 2025, 8:00 AM EST - 7 months ago

ProQR to Participate in 8th Annual Evercore Healthcare Conference

Nov 6, 2025, 9:30 AM EST - 8 months ago

ProQR Therapeutics Earnings release: Q3 2025

2025-11-06T12:21:19.000Z - 8 months ago

ProQR Therapeutics reports Q3 (EUR 0.10) vs (EUR 0.10) last year

Nov 6, 2025, 7:00 AM EST - 8 months ago

ProQR Announces Third Quarter 2025 Operating and Financial Results

Nov 3, 2025, 10:00 AM EST - 8 months ago

ProQR Therapeutics Transcript: Study Update

Nov 3, 2025, 10:00 AM EST - 8 months ago

ProQR Therapeutics Press release: Study Update

Nov 3, 2025, 10:00 AM EST - 8 months ago

ProQR Therapeutics Slides: Study Update

Oct 21, 2025, 1:00 PM EDT - 9 months ago

ProQR Therapeutics Transcript: Chardan’s 9th Annual Genetic Medicines Conference

2025-10-20T12:05:08.000Z - 9 months ago

ProQR Therapeutics receives CTA authorization for AX-0810

Oct 20, 2025, 8:00 AM EDT - 9 months ago

ProQR Receives CTA Authorization for AX-0810 and Announces Virtual Investor and Analyst Event on November 3, 2025

2025-10-16T16:15:25.000Z - 9 months ago

ProQR Therapeutics management to meet with Citizens JMP

Oct 13, 2025, 8:30 AM EDT - 9 months ago

ProQR to Participate in Upcoming Investor Conferences in October 2025

Aug 7, 2025, 9:30 AM EDT - 11 months ago

ProQR Therapeutics Earnings release: Q2 2025

2025-08-07T11:32:48.000Z - 11 months ago

ProQR Therapeutics reports Q2 EPS (EUR 0.21) vs. (EUR 0.13) last year

2025-08-07T11:32:17.000Z - 11 months ago

ProQR Therapeutics sees cash runway into mid-2027

Aug 7, 2025, 7:00 AM EDT - 11 months ago

ProQR Announces Second Quarter 2025 Operating and Financial Results

Jul 28, 2025, 8:00 AM EDT - 1 year ago

ProQR Announces Upcoming Presentation at RNA Editing Summit

2025-07-11T18:15:22.000Z - 1 year ago

ProQR Therapeutics price target raised to $5 from $4 at Evercore ISI

Jun 26, 2025, 4:30 PM EDT - 1 year ago

ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP

2025-05-13T12:01:54.000Z - 1 year ago

ProQR Therapeutics price target lowered to $9 from $15 at Oppenheimer

May 12, 2025, 8:00 AM EDT - 1 year ago

ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences

May 8, 2025, 11:30 AM EDT - 1 year ago

ProQR Therapeutics Transcript: The Citizens JMP Life Sciences Conference 2025

May 8, 2025, 7:00 AM EDT - 1 year ago

ProQR Announces First Quarter 2025 Operating and Financial Results

May 7, 2025, 6:00 PM EDT - 1 year ago

ProQR Therapeutics Earnings release: Q1 2025

May 2, 2025, 8:00 AM EDT - 1 year ago

ProQR Announces Webcast of Presentation at the 2025 Citizens Life Sciences Conference

May 1, 2025, 8:00 AM EDT - 1 year ago

ProQR Announces Annual General Meeting of Shareholders to be Held June 3, 2025

Apr 14, 2025, 7:00 AM EDT - 1 year ago

ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth

Mar 13, 2025, 1:30 PM EDT - 1 year ago

ProQR Therapeutics Annual report: Q4 2024

Mar 13, 2025, 1:30 PM EDT - 1 year ago

ProQR Therapeutics Press release: Q4 2024

Mar 13, 2025, 8:00 AM EDT - 1 year ago

ProQR Therapeutics Registration statement: Registration Filing

Mar 13, 2025, 7:00 AM EDT - 1 year ago

ProQR Announces Year End 2024 Operating and Financial Results

Dec 11, 2024, 10:00 AM EST - 1 year ago

ProQR Therapeutics Transcript: AGM 2024

Dec 10, 2024, 8:00 AM EST - 1 year ago

ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist

Nov 7, 2024, 9:30 AM EST - 1 year ago

ProQR Therapeutics Earnings release: Q3 2024

Oct 25, 2024, 4:45 PM EDT - 1 year ago

ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement

Oct 22, 2024, 10:15 PM EDT - 1 year ago

ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement

Oct 22, 2024, 4:01 PM EDT - 1 year ago

ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares

Oct 7, 2024, 8:00 AM EDT - 1 year ago

ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society

Sep 30, 2024, 8:00 AM EDT - 1 year ago

ProQR Therapeutics Registration statement: Registration Filing

Sep 17, 2024, 9:10 AM EDT - 1 year ago

ProQR Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 10, 2024, 4:30 PM EDT - 1 year ago

ProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare Conference

Aug 8, 2024, 7:21 AM EDT - 2 years ago

ProQR Therapeutics Earnings release: Q2 2024

May 9, 2024, 8:00 AM EDT - 2 years ago

ProQR Therapeutics Transcript: Status Update

May 9, 2024, 8:00 AM EDT - 2 years ago

ProQR Therapeutics Press release: Status Update

May 9, 2024, 8:00 AM EDT - 2 years ago

ProQR Therapeutics Slides: Status Update

May 9, 2024, 7:00 AM EDT - 2 years ago

ProQR Announces First Quarter 2024 Operating and Financial Results

May 9, 2024, 2:00 AM EDT - 2 years ago

ProQR Therapeutics Earnings release: Q1 2024

Apr 23, 2024, 7:00 AM EDT - 2 years ago

ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024

Apr 22, 2024, 4:31 PM EDT - 2 years ago

ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting

Apr 19, 2024, 7:00 AM EDT - 2 years ago

ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio

Mar 13, 2024, 7:00 AM EDT - 2 years ago

ProQR Announces Year End 2023 Operating and Financial Results

Mar 13, 2024, 6:00 AM EDT - 2 years ago

ProQR Therapeutics Annual report: Q4 2023

Mar 13, 2024, 6:00 AM EDT - 2 years ago

ProQR Therapeutics Earnings release: Q4 2023

Jan 19, 2024, 7:00 AM EST - 2 years ago

ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024

Jan 5, 2024, 7:00 AM EST - 2 years ago

ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration

Dec 8, 2023, 7:30 AM EST - 2 years ago

ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets

Nov 7, 2023, 7:00 AM EST - 2 years ago

ProQR Announces Third Quarter 2023 Operating and Financial Results

Nov 7, 2023, 5:00 AM EST - 2 years ago

ProQR Therapeutics Earnings release: Q3 2023

Nov 6, 2023, 7:00 AM EST - 2 years ago

ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing

Sep 28, 2023, 8:00 AM EDT - 3 years ago

ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference

Sep 7, 2023, 8:00 AM EDT - 3 years ago

ProQR Announces Webcast of Presentation at the Upcoming HC Wainwright 25th Annual Global Investment Conference

Aug 3, 2023, 7:00 AM EDT - 3 years ago

ProQR Announces Second Quarter 2023 Operating and Financial Results

Aug 3, 2023, 5:00 AM EDT - 3 years ago

ProQR Therapeutics Earnings release: Q2 2023

Aug 1, 2023, 7:00 AM EDT - 3 years ago

ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR's Sepofarsen and Ultevursen Ophthalmic Assets

Jul 6, 2023, 7:00 AM EDT - 3 years ago

ProQR to Present Data on its Axiomer® RNA Editing Technology at RNA Editing Summit

May 16, 2023, 5:00 AM EDT - 3 years ago

ProQR Therapeutics Earnings release: Q1 2023

May 9, 2023, 8:00 AM EDT - 3 years ago

ProQR to Present its Axiomer® RNA Editing Technology at TIDES USA 2023

Apr 20, 2023, 8:00 AM EDT - 3 years ago

ProQR Announces Upcoming Investor Conferences in April and May

Apr 18, 2023, 8:00 AM EDT - 3 years ago

ProQR Announces Annual Meeting of Shareholders to be Held May 17, 2023

Filvul Jul. 2 at 2:12 PM

$PRQR

0 · Reply

Filvul Jul. 2 at 11:03 AM

$PRQR

0 · Reply

justfacts1 Jul. 1 at 5:20 PM

$PRQR first open market buy in company history!

1 · Reply

justfacts1 Jul. 1 at 5:19 PM

$PRQR

0 · Reply

Geert07 Jul. 1 at 10:39 AM

$PRQR $PRQR Insider buying is always a good indication. Sign of confidence.

1 · Reply

struminbanjobio Jul. 1 at 4:44 AM

$PRQR run up locked in with insiders buying, $LLY loaded up and tutes bought more $SLS $ABVX

0 · Reply

ACH50 Jul. 1 at 2:20 AM

$PRQR Bart Filius in with 150,000 share purchase. This gentleman has shared good company, Galapagos, Sanofi…it’s all starting to come together, finally…

0 · Reply

FilingTracker Jun. 30 at 8:02 PM

$PRQR Insider started a new position: https://filingtracker.ai/filing/1612940/0001104659-26-079316

0 · Reply

ACH50 Jun. 30 at 12:56 PM

1 · Reply

struminbanjobio Jun. 29 at 11:29 PM

$SLS $PRQR big movers today 🥳🥳😉😉

0 · Reply

topstockalerts Jun. 29 at 8:39 PM

$PRQR this stock has some swagger today 😎

0 · Reply

Herrfranz Jun. 29 at 5:55 PM

$PRQR added

0 · Reply

Bobfree Jun. 29 at 5:19 PM

$PRQR it was a warrantless offering, there is no arbitrage play. Funds bought because 1.81 is a steal given those results.

2 · Reply

struminbanjobio Jun. 29 at 4:00 PM

$PRQR only the beginning ;)

0 · Reply

Filvul Jun. 29 at 3:00 PM

0 · Reply

Geert07 Jun. 29 at 2:55 PM

$PRQR https://www.proqr.com/files/2026-06/ProQR-25-June-2026-NTCP-announcement.pdf Based on the overview in slide 3, PRQR should have at least three fully owned products in the clinic by the end of 2027. And that is not taking into account any of the undisclosed programmes that are partnered with Lilly. The company is quickly growing into a multi programme biotech. Looks like they are finally picking up the pace. Hopefully there will be some substantial milestone payments from Lilly to fund the pipeline.

1 · Reply

Filvul Jun. 29 at 2:46 PM

$PRQR I still think this can double by year-end...

1 · Reply

dirkfrank Jun. 28 at 10:24 AM

$PRQR at every announcement the stock price slumps. Immediate public offering 60M$ of which $LLY putting 9M$ in the bowl. Getting tired of watching and waiting. Classic biotech what’s another year. Bad week for shareholders. Wonder what they are thinking at Van Herk. I’m not amused.

3 · Reply

biochirp Jun. 26 at 7:39 PM

$PRQR Lily just went up 10 PRQRs 🤣

1 · Reply

johnnygogogo Jun. 26 at 5:45 PM

$PRQR wow guys. To think you can buy it at $1.50 and maybe double up to $3! Thanks smooth brain Chardan. Sorry your didn’t get any of the allocation. Nobody, literally nobody is here for a 100% gain. $3 is below Lilly’s total cost basis, even after this current round.

0 · Reply

anachartanalyst Jun. 26 at 1:01 PM

$PRQR https://anachart.com/wp-content/uploads/2026/06/1782478874_soc-img.jpg

2 · Reply

struminbanjobio Jun. 25 at 10:24 PM

$PRQR run up ax-0811 from here. Tutes committing at $1.81 is a bullish signal

1 · Reply

Market Cap	190.70M
Revenue (ttm)	18.00M
Net Income (ttm)	-47.73M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-265.17%
Debt to Equity Ratio	0.13

Volume	1,189,300
Avg Vol	961,534
Day's Range	N/A - N/A
Shares Out	105.36M
Stochastic %K	73%
Beta	0.04
Analysts	Strong Sell
Price Target	$8.25